Two people can smoke the same amount, live in the same place, and eat the same food, and one gets cancer while the other does not. A new experiment offers direct evidence for part of why, though it was conducted in mice and it changes nothing about anyone's medical care.
Researchers at the University of Cambridge exposed genetically different mice to the same DNA damage and found that inherited genetic background influenced not only whether tumors developed but the evolutionary path those tumors took afterward. The paper, titled "Genetic background sets the trajectory of experimental cancer evolution," was published in Nature.
The point is that this is a controlled experiment rather than another observational study. In people, inheritance and environment are hopelessly entangled. Families share genes and also share diets, neighborhoods, air and habits. In mice, researchers can hold the exposure constant and vary only the genetic background.
What the Experiment Showed
The design isolates a variable that human studies cannot. Every animal received comparable DNA damage. The genetic backgrounds differed. The tumors that emerged differed too, not merely in how often they appeared but in how they developed.
That distinction between risk and trajectory is the novel part. It has long been understood that inherited variation affects cancer susceptibility, which is the basis of everything from BRCA testing to Lynch syndrome surveillance. What this work adds is evidence that inherited background also shapes which mutations a tumor accumulates and which evolutionary route it follows once it has started.
If that holds in humans, the implication would be that two people with the same inherited risk factor and the same exposure might still develop biologically different cancers requiring different treatment. That is a meaningful idea, and it is a hypothesis rather than a finding about people.
The mouse caveat is not a formality. Mice are inbred, short-lived, and exposed to controlled damage at doses chosen by researchers. Human cancer develops over decades under messy, variable, low-level exposures. Findings in this system frequently fail to reproduce in humans, and the history of oncology is full of mechanisms that were real in mice and irrelevant in patients.
What This Cannot Tell You About Your Own Risk
For a reader with cancer in the family, the honest answer to "how much does my inheritance matter versus my exposure" is that it depends enormously on which cancer and which inheritance, and that this study does not move the number.
A small proportion of cancers are driven by high-penetrance inherited mutations in single genes. BRCA1 and BRCA2 in breast and ovarian cancer, mismatch repair genes in Lynch syndrome, and a handful of others. In those families, the inherited contribution is large, identifiable by testing, and actionable through earlier and more intensive surveillance or risk-reducing surgery.
Most cancer is not that. The majority arises from a combination of many common genetic variants each contributing a little, accumulated exposures, and chance mutations during ordinary cell division. Chance is a larger contributor than most people find comfortable.
Polygenic risk scores, which aggregate many small-effect variants, are an active research area and are not established for routine clinical use in most cancers. They also carry the same ancestry-transferability problem that affects genetic risk prediction generally, performing less well outside the populations they were developed in.
What Actually Determines Whether You Should Do Something Differently
Family history remains the practical tool, and it is more informative than most people realize.
The features that raise concern are cancer diagnosed at unusually young ages, multiple relatives with the same or related cancers, cancer in both of a paired organ, rare cancers, and certain combinations such as breast and ovarian cancer or colorectal and endometrial cancer in one family. Ancestry matters for some specific mutations.
Someone with those features should discuss referral to genetic counseling with a clinician. Genetic counselors assess whether testing is warranted, which test is appropriate, and what a result would and would not mean, including the possibility of an ambiguous result that answers nothing.
Genetic counseling can identify high-penetrance syndromes and change surveillance accordingly. What it cannot do is tell most people how much of their personal risk is genetic versus environmental, because for most people that question has no precise answer with current tools.
Someone without those family history features is generally served by standard age-appropriate screening. Nothing in this study alters what that screening is or when it should start.
What Would Have to Happen for This to Matter Clinically
The path from a mouse result to a change in patient care runs through several stages, none of which has begun.
Researchers would need to demonstrate that the same relationship between inherited background and tumor evolution operates in humans, likely through large studies pairing germline genetic data with tumor sequencing. They would then need to show that knowing a person's background changes a decision, either about surveillance intensity or about treatment selection. And they would need evidence that acting on that information improves outcomes rather than simply generating more testing.
That sequence takes years and often stalls. The realistic near-term value of this work is to researchers designing the next experiment.
In the meantime, the modifiable contributors to cancer risk are the unglamorous ones that have not changed: not smoking, limiting alcohol, maintaining physical activity, sun protection, HPV and hepatitis B vaccination, and completing the screening that applies to your age and history.
MedicalDaily will report on any human validation of these findings and on developments in clinical genetic risk assessment.
The confirmed finding is that in a controlled mouse experiment, inherited genetic background shaped how tumors evolved after identical DNA damage. The people most affected in the near term are none, because this is animal research. The most reasonable action for a reader with a strong family history is a conversation about genetic counseling, which was already true yesterday. The central uncertainty is whether the relationship holds in humans at all.
Frequently Asked Questions
What did the study find? That in mice given the same DNA damage, inherited genetic background influenced both whether tumors developed and how those tumors evolved.
Was this done in people? No. It was a controlled mouse experiment, which is why it could isolate genetics from environment in a way human studies cannot.
Does this change cancer screening? No. No screening recommendation changes on the basis of animal research.
How much of my cancer risk is inherited? It depends on the cancer and the family. A small share of cancers come from high-penetrance inherited mutations. Most involve many small genetic contributions, exposures, and chance.
Should I get genetic testing? Discuss it with a clinician if your family has cancers diagnosed young, multiple affected relatives, or certain cancer combinations. Genetic counseling assesses whether testing is warranted.
What about polygenic risk scores? They are an active research area, not established for routine use in most cancers, and they perform less well outside the populations used to develop them.
What can I actually do? Avoid tobacco, limit alcohol, stay physically active, protect against sun exposure, get HPV and hepatitis B vaccination, and complete age-appropriate screening.
